[1] 国家消化系疾病临床医学研究中心(上海), 国家消化道早癌防治中心联盟, 中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组,等. 中国居民家庭幽门螺杆菌感染的防控和管理专家共识(2021年)[J]. 中华消化杂志, 2021, 41(4):221-233. [2] Hooi JKY, Lai WY, Ng WK, et al.Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis[J]. Gastroenterology, 2017, 153(2): 420-429. [3] 中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组, 全国幽门螺杆菌研究协作组, 刘文忠,等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学, 2017, 22(6):346-360. [4] O'Connor A, Furuta T, Gisbert JP, et al. Review-treatment of Helicobacter pylori infection 2020[J]. Helicobacter, 2020, 25: e12743. [5] Salazar LF, Valle-Munoz J. Treating Helicobacter pylori infection in the face of growing antibiotic resistance[J]. Rev Esp Enferm Dig, 2019, 111(9): 653-655. [6] Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, et al. Helicobacter pylori drug resistance: Therapy changes and challenges[J]. Expert Rev Gastroent, 2018, 12(8): 819-827. [7] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibflity testing; Twenty second informational supplement[S]. PA: Clinical and Laboratory Standards Institute, 2013. [8] Sukri A, Hanafiah A, Mohamad Zin N, et al.Epidemiology and role of Helicobacter pylori virulence factors in gastric cancer carcinogenesis[J]. Apmis, 2020, 128(2): 150-161. [9] Bujanda L, Nyssen OP, Vaira D, et al.Antibiotic resistance prevalence and trends in patients infected with Helicobacter pylori in the period 2013-2020: Results of the European registry on H. pylori management (hp-Eureg)[J]. Antibiotics, 2021, 10(9): 1058. [10] 宫艳艳, 李连香, 归巧娣. 西安地区体检人群幽门螺杆菌感染及分型状况调查[J]. 现代检验医学杂志, 2021, 36(4):116-118,128. [11] 刘涛,李睿,龚琳,等.胃幽门螺杆菌感染后Semaphorin 5A致胃癌可能机制的研究[J].分子诊断与治疗杂志,2019,11(3):189-193. [12] 钱君, 张碧文, 李佳, 等. 无锡某院幽门螺杆菌筛查人群感染流行病学及耐药性[J]. 中华医院感染学杂志, 2022, 32(18):2794-2798. [13] Zamani M, Ebrahimtabar F, Zamani V, et al.Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection[J]. Aliment Pharm Therapeutics, 2018, 47(7): 868-876. [14] Boyanova L, Hadzhiyski P, Kandilarov N, et al.Multidrug resistance in Helicobacter pylori: Current state and future directions[J]. Expert Rev Clin Pharmacol, 2019, 12(9): 909-915. [15] Zou Y, Qian X, Liu X, et al.The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis[J]. Helicobacter, 2020, 25(4): e12714. [16] 张世武, 吴凯, 张钰坤, 等.淮南市2家医院门诊患者幽门螺杆菌感染状况及耐药性分析[J]. 中国临床保健杂志, 2022, 25(3):352-354. [17] 周雄杰, 吕志刚, 柳家红, 等. 幽门螺杆菌感染患者影响因素及耐药性分析[J]. 中华医院感染学杂志, 2018, 28(16):2490-2493. [18] Cardos I A, Zaha D C, Sindhu R K, et al.Revisiting therapeutic strategies for H. pylori treatment in the context of antibiotic resistance: Focus on alternative and complementary therapies[J]. Molecules, 2021, 26(19): 6078. [19] Bluemel B, Goelz H, Goldmann B, et al.Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018[J]. Clin Microbiol Infect, 2020, 26(2): 235-239. [20] 吕农华, 谢川. 我国幽门螺杆菌感染研究的回顾与展望[J]. 中华消化杂志, 2021, 41(4):217-220. [21] Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in World Health Organization regions[J]. Gastroenterology, 2018, 155(5): 1372-1382. e17. |